Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion

Blood

Volumn 120, Issue 17, 2012, Pages 3541-3554

  Tripodo, Claudio ^a   Sangaletti, Sabina ^b   Guarnotta, Carla ^a   Piccaluga, Pier P ^c   Cacciatore, Matilde ^a   Giuliano, Michela ^a   Franco, Giovanni ^a   Chiodoni, Claudia ^b   Sciandra, Marika ^d   Miotti, Silvia ^b   Calvaruso, Giuseppe ^a   Carè, Alessandra ^e   Florena, Ada M ^a   Scotlandi, Katia ^d   Orazi, Attilio ^f   Pileri, Stefano A ^c   Colombo, Mario P ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; OSTEONECTIN; THROMBOPOIETIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW DEPRESSION; CELL EXPANSION; CONTROLLED STUDY; FEMALE; FIBROSIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STROMA CELL; MOUSE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84868582302     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-398537     Document Type: Article

References (55)

1. Bianco P. Bone and the hematopoietic niche: a tale of two stem cells. Blood. 2011;117(20):5281-5288.
2. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010; 464(7290):852-857.
3. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
4. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7(2):118-129. (Pubitemid 46164747)
5. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191.
6. Tripodo C, Sangaletti S, Piccaluga PP, et al. The bone marrow stroma in hematological neoplasms: a guilty bystander. Nat Rev Clin Oncol. 2011;8(8):456-466.
7. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132. (Pubitemid 41323513)
8. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96(10):3374-3380.
9. Tripodo C, Di Bernardo A, Ternullo MP, et al. CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. Haematologica. 2009;94(1):127-130.
10. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.
11. Buesche G, Ganser A, Schlegelberger B, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia. 2007;21(12):2420-2427. (Pubitemid 350148883)
12. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings: a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85(4):226-232.
13. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111(4):1862-1865. (Pubitemid 351451494)
14. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-762.
15. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;19(10):2239-2241.
16. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255-1265. (Pubitemid 30235956)
17. Thiele J, Kvasnicka HM, Beelen DW, et al. Relevance and dynamics of myelofibrosis regarding hematopoietic reconstitution after allogeneic bone marrow transplantation in chronic myelogenous leukemia: a single center experience on 160 patients. Bone Marrow Transplant. 2000;26(3):275-281. (Pubitemid 30614406)
18. Buesche G, Hehlmann R, Hecker H, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia: prospective long-term results from a randomized-controlled trial. Leukemia. 2003;17(12):2444-2453. (Pubitemid 38072583)
19. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2010;29(2):295-307.
20. Piconese S, Costanza M, Tripodo C, et al. The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. J Autoimmun. 2011;37(4):300-310.
21. Clark CJ, Sage EH. A prototypic matricellular protein in the tumor microenvironment: where there's SPARC, there's fire. J Cell Biochem. 2008;104(3):721-732. (Pubitemid 351830824)
22. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21(9):1931-1936. (Pubitemid 47299966)
23. DiMartino JF, Lacayo NJ, Varadi M, et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 2006;20(3):426-432. (Pubitemid 43291739)
24. Fenouille N, Puissant A, Dufies M, et al. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res. 2010;70(23):9659-9670.
25. Sangaletti S, Tripodo C, Cappetti B, et al. SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. Am J Pathol. 2011;179(6):3000-3010.
26. Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood. 1996; 87(12):5006-5015.
27. Zhu H, Guo ZK, Jiang XX, et al. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc. 2010;5(3):550-560.
28. Walenda T, Bokermann G, Ventura Ferreira MS, et al. Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Exp Hematol. 2011;39(6):617-628.
29. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67(23):11438-11446. (Pubitemid 350248572)
30. Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood. 2011;117(13):3596-3608.
31. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
32. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131(2):324-336. (Pubitemid 47592917)
33. Delany AM, Kalajzic I, Bradshaw AD, Sage EH, Canalis E. Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology. 2003;144(6):2588-2596. (Pubitemid 36637090)
34. Nie J, Sage EH. SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. J Biol Chem. 2009;284(2):1279-1290.
35. Pallotta I, Lovett M, RiceW, Kaplan DL, Balduini A. Bone marrow osteoblastic niche: a new model to study physiological regulation of megakaryopoiesis. PLoS One. 2009;4(12):e8359.
36. Kahai S, Vary CP, Gao Y, Seth A. Collagen, type V, alpha1 (COL5A1) is regulated by TGF-beta in osteoblasts. Matrix Biol. 2004;23(7):445-455. (Pubitemid 39576659)
37. Izu Y, Sun M, Zwolanek D, et al. Type XII collagen regulates osteoblast polarity and communication during bone formation. J Cell Biol. 2011;193(6):1115-1130.
38. Lane SW, Sykes SM, Al-Shahrour F, et al. Apc-(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood. 2010;115(17):3489-3497.
39. Wang J, Fernald AA, Anastasi J, Le Beau MM, Qian Z. Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood. 2010;115(17):3481-3488.
40. Atorrasagasti C, Aquino JB, Hofman L, et al. SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-beta1 and PDGF. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G739-G748.
41. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol. 2007;171(4):1104-1112. (Pubitemid 47582886)
42. Schellings MW, Vanhoutte D, Swinnen M, et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med. 2009;206(1):113-123.
43. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)- 8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.
44. Bock O, Loch G, Büsche G, von Wasielewski R, Schlué J, Kreipe H. Aberrant expression of platelet-derived growth factor (PDGF) and PDGF receptor-alpha is associated with advanced bone marrow fibrosis in idiopathic myelofibrosis. Haematologica. 2005;90(1):133-134. (Pubitemid 40193767)
45. Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood. 2005;105(9):3493-3501. (Pubitemid 40628191)
46. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A. 1992;89(4):1281-1285.
47. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH. SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J Biol Chem. 1999;274(45):32145-32152.
48. Wang JC, Lai S, Guo X, et al. Attenuation of fibrosis in vitro and in vivo with SPARC siRNA. Arthritis Res Ther. 2010;12(2):R60.
49. Kogan SC, Ward JM, Anver MR, et al. Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium: Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100(1):238-245. (Pubitemid 35177453)
50. Siva K, Jaako P, Miharada K, et al. SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q- myelodysplastic syndrome [published online ahead of print April 5, 2012]. Leukemia. doi:10.1038/leu.2012.97.
51. Kopp HG, Hooper AT, Broekman MJ, et al. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest. 2006;116(12): 3277-3291. (Pubitemid 44878642)
52. Evrard S, Bluteau O, Tulliez M, et al. Thrombospondin-1 is not the major activator of TGF-beta1 in thrombopoietin-induced myelofibrosis. Blood. 2011; 117(1):246-249.
53. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520-8530.
54. Liersch R, Gerss J, Schliemann C, et al. Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood. 2012;119(22):5215-5220.
55. Varricchio L, Mancini A, Migliaccio AR. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol. 2009;2(3):315-334.